| Cat.No. | Name | Information |
|---|---|---|
| M40905 | Remternetug | Remternetug is an IgG1 monoclonal antibody that targets the pyroglutamate modification of the third amino acid of the amyloid beta peptide present only in brain amyloid plaques, and can be used in studies related to Alzheimer's disease (AD). |
| M40876 | Ebdarokimab | Ebdarokimab is a monoclonal antibody to IL-12p40/IL-23 that can be used in studies related to inflammatory bowel disease (IBD). |
| M40870 | RVT-3101 | RVT-3101 is a potential first-in-class anti-tumor necrosis factor (TNF)-like ligand 1A (TL1A) monoclonal antibody for use in studies related to inflammatory bowel disease (IBD). |
| M40854 | Elranatamab | Elranatamab is a humanized IgG2ҡ bispecific T-cell inducing antibody that targets CD3 and B-cell maturation antigen (BCMA) on the surface of T-cells, resulting in activation of T-cells and the release of a variety of pro-inflammatory cytokines that lead to multiple myeloma cell lysis. It can be used in studies related to relapsed or refractory multiple myeloma (RRMM). |
| M40646 | CDX-1140 | CDX-1140 is an anti-CD40 human IgG2 monoclonal antibody that activates dendritic cells and B cells and drives NF-kB stimulation in CD40-expressing reporter cell lines. |
| M40611 | PF-04236921 | PF-04236921 is a fully human IgG2 monoclonal antibody targeting the interleukin IL-6 for studies related to Crohn's disease and rheumatoid arthritis. |
| M40609 | Eblasakimab | Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Rα1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD). |
| M40602 | Alacizumab | Alacizumab is a monoclonal antibody against VEGFR2 that can be used in cancer-related studies. |
| M40600 | Ebronucimab | Ebronucimab is a monoclonal antibody to PCSK9 that can be used in studies related to hypercholesterolemia. |
| M40598 | Serclutamab | Serclutamab is a monoclonal antibody to EGFR that can be used in studies related to solid tumors. |
| M40597 | Ametumumab | Ametumumab is a recombinant fully human anti-EGFR monoclonal antibody that can be used in studies related to colorectal cancer. |
| M40596 | Pimurutamab | Pimurutamab is a monoclonal antibody to EGFR that can be used in tumor-related studies. |
| M40595 | Pidilizumab | Pidilizumab is a monoclonal antibody to PD-1 that can be used in studies related to diffuse large B-cell lymphoma (DLBCL). |
| M40594 | Genolimzumab | Genolimzumab is a PD-1 monoclonal antibody that can be used in studies related to peripheral T-cell lymphoma (PTCL). |
| M40593 | Brolucizumab | Brolucizumab is a humanized single-chain anti-VEGF-A variable antibody fragment (scFv) that can be used in studies related to macular degeneration. |
| M40592 | Certolizumab | Certolizumab is a recombinant, polyethylene glycolated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumor necrosis factor (TNF)-alpha, and may be used in psoriasis-related studies. |
| M40552 | Osemitamab | Osemitamab (TST001) is a recombinant humanized, IgG1 antibody targeting CLDN18.2, consisting of the human mouse monoclonal TST001 γ-1 chain polymerized via disulfide bonding with the human mouse monoclonal TST001 κ-chain dimer (ACI). It can be used in studies related to bile duct tumors. |
| M31300 | Faricimab | Faricimab is a bispecific antibody targeting Ang II and VEGF-A for studies related to eye disease and cardiovascular disease. |
| M31299 | Zebituzumab | Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma. |
| M25443 | Necitumumab | Necitumumab is a second-generation fully humanized immunoglobulin G1 (IgG1), epidermal growth factor (EGFR) receptor monoclonal antibody that specifically blocks the ligand binding site of EGFR. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
